Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
Seagen Inc.
AstraZeneca
University of California, Irvine
Neonc Technologies, Inc.
ViroMissile, Inc.
EMD Serono
Arcus Biosciences, Inc.
Jazz Pharmaceuticals
Seagen Inc.
Merus B.V.
Pfizer
Arvinas Inc.